Does Flaxseed Cardiometabolic Meta-Analysis work?

The current Migaku evidence database contains 2 reusable source documents for Flaxseed Cardiometabolic Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove. - Unhealthy aging is a growing global concern, characterized by the accelerated decline in physiological and metabolic functions, leading to increased susceptibility to age-related diseases. [Kunutsor Setor K. (2025); evidence level 3] - Among these are cardiometabolic diseases, including hypertension, metabolic syndrome (MetS), metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular diseases (CVDs), which collectively represent a significant public health burden. [Kunutsor Setor K. (2025); evidence level 3] - This condition, characterized by fat accumulation in the liver independent of alcohol consumption, often coexists with obesity, MetS, and T2D, significantly increasing the risk of liver cirrhosis and CVD []. [Kunutsor Setor K. (2025); evidence level 3] - Results: Compared with the HFD group, curcumin-flaxseed oil supplementation significantly reduced serum TG, TC, and LDL-C levels, while HDL-C remained unchanged. [Wei PH (2026); evidence level 4] - Hepatic TG and TC accumulation also decreased significantly, accompanied by increased fecal TG and TC excretion, with a more pronounced effect in the high-dose group. [Wei PH (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.